EXTENDEDLONGDESC

00720.00

Red blood cell antigen typing, dna, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common rbc alleles reported

00025.00

Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (lc-ms/ms) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps

00950.00

Oncology (ovarian) biochemical assays of five proteins (apolipoprotein a-1, ca 125 ii, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score

00760.00

Oncology (prostate) gene expression profile by real-time rt-pcr of 3 genes (erg, pca3, and spdef), urine, algorithm reported as risk score

00114.43

Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including dna authentication in comparison to buccal dna, per date of service

00597.91

Helicobacter pylori detection and antibiotic resistance, dna, 16s and 23s rrna, gyra, pbp1, rdxa and rpob, next generation sequencing, formalin-fixed paraffin embedded or fresh tissue or fecal sample, predictive, reported as positive or negative for resistance to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline and rifabutin

00107.00

Oncology (breast cancer), erbb2 (her2) copy number by fish, tumor cells from formalin fixed paraffin embedded tissue isolated using image-based dielectrophoresis (dep) sorting, reported as erbb2 gene amplified or non-amplified

00427.26

Infectious disease (bacterial), strain typing by whole genome sequencing, phylogenetic-based report of strain relatedness, per submitted isolate

00114.43

Prescription drug monitoring, evaluation of drugs present by lc-ms/ms, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds and metabolites

00163.96

Oncology (hematolymphoid neoplasia), rna, bcr/abl1 major and minor breakpoint fusion transcripts, quantitative pcr amplification, blood or bone marrow, report of fusion not detected or detected with quantitation

00091.66

Oncology (hematolymphoid neoplasia), jak2 mutation, dna, pcr amplification of exons 12-14 and sequence analysis, blood or bone marrow, report of jak2 mutation not detected or detected

03002.09

Oncology (thyroid), microrna profiling by rt-pcr of 10 microrna sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy

03675.00

Oncology, rna, gene expression by whole transcriptome sequencing, formalin-fixed paraffin embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents

00760.00

Oncology (prostate), detection of 8 autoantibodies (arf 6, nkx3-1, 5'-utr-bmi1, cep 164, 3'-utr-ropporin, desmocollin, aurkaip-1, csnk2a2), multiplexed immunoassay and flow cytometry serum, algorithm reported as risk score

01950.00

Targeted genomic sequence analysis panel, non-small cell lung neoplasia, dna and rna analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence or absence of variants and associated therapy(ies) to consider

00248.51

Oncology (acute myelogenous leukemia), dna, genotyping of internal tandem duplication, p.d835, p.i836, using mononuclear cells, reported as detection or non-detection of flt3 mutation and indication for or against the use of midostaurin

00034.19

Glycosylated acute phase proteins (glyca), nuclear magnetic resonance spectroscopy, quantitative

00114.43

Tenofovir, by liquid chromatography with tandem mass spectrometry (lc-ms/ms), urine, quantitative

03600.00

Oncology (thyroid), dna and mrna of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("positive, high probability of malignancy" or "negative, low probability of malignancy")

00121.91

Jak2 (janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15

00134.13

Drug metabolism (warfarin drug response), targeted sequence analysis (ie, cyp2c9, cyp4f2, vkorc1, rs12777823)

00174.81

Comt (catechol-o-methyltransferase) (drug metabolism) gene analysis, c.472g>a (rs4680) variant

00466.17

Tpmt (thiopurine s-methyltransferase), nudt15 (nudix hydroxylase 15)(eg, thiopurine metabolism), gene analysis, common variants (ie, tpmt *2, *3a, *3b, *3c, *4, *5, *6, *8, *12; nudt15 *3, *4, *5)

00540.99

Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative

04780.00

Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses

03500.00

Targeted genomic sequence analysis, solid organ neoplasm, dna analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden

00029.60

Vitamin d, 25 hydroxy d2 and d3, by lc-ms/ms, serum microsample, quantitative

00013.74

Deoxyribonucleic acid (dna) antibody, double stranded, high avidity

00409.90

Bcr/abl1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative

00017.21

Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, igm

00017.21

Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, igg

00014.86

Tick-borne relapsing fever borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, igm

00014.86

Tick-borne relapsing fever borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, igg

03873.00

Oncology (breast ductal carcinoma in situ), mrna, gene expression profiling by real-time rt-pcr of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score

00407.43

Flt3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (itd) variants, quantitative

03873.00

Oncology (prostate), mrna, gene expression profiling by real-time rt-pcr of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score

02919.60

Oncology (solid organ neoplasia), dna, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)

00407.43

Npm1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative

02916.60

Targeted genomic sequence analysis panel, acute myelogenous leukemia, dna analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements

00246.92

Prescription drug monitoring, evaluation of drugs present by liquid chromatography tandem mass spectrometry (lc-ms/ms), urine or blood, 31 drug panel, reported as quantitative results, detected or not detected, per date of service

00033.86

Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of hdl, ldl, and vldl by vertical auto profile ultracentrifugation

00198.74

Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service

03240.00

Cardiology (heart transplant), cell-free dna, pcr assay of 96 dna target sequences (94 single nucleotide polymorphism targets and two control targets), plasma

00322.96

Oncology (merkel cell carcinoma), detection of antibodies to the merkel cell polyoma virus oncoprotein (small t antigen), serum, quantitative

00322.96

Oncology (merkel cell carcinoma), detection of antibodies to the merkel cell polyoma virus capsid protein (vp1), serum, reported as positive or negative

00759.05

Twin zygosity, genomic-targeted sequence analysis of chromosome 2, using circulating cell-free fetal dna in maternal blood

00025.10

Transcutaneous measurement of five biomarkers (tissue oxygenation [sto2], oxyhemoglobin [cthbo2], deoxyhemoglobin [cthbr], papillary and reticular dermal hemoglobin concentrations [cthb1 and cthb2]), using spatial frequency domain imaging (sfdi) and multi-spectral analysis

00380.72

Autoimmune (systemic lupus erythematosus), igg and igm analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score

00750.00

Neurology (autism), 32 amines by lc-ms/ms, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder

00031.33

Antibody, treponema pallidum, total and rapid plasma reagin (rpr), immunoassay, qualitative

00018.09

Syphilis test, non-treponemal antibody, immunoassay, qualitative (rpr)

01897.00

Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [mmp-1], carcinoembryonic antigen-related cell adhesion molecule 6 [ceacam6], hyaluronoglucosaminidase [hyal1], highly expressed in cancer protein [hec1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score

00142.63

Candida species panel (c. albicans, c. glabrata, c. parapsilosis, c. kruseii, c tropicalis, and c. auris), amplified probe technique with qualitative report of the presence or absence of each species

00380.00

Oncology (colorectal), microrna, rt-pcr expression profiling of mir-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression sco

00676.37

Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4n, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14a, *14b, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xn)

00600.00

Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (list separately in addition to code for primary procedure)

00450.91

Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, cyp2d6-2d7 hybrid gene) (list separately in addition to code for primary procedure)

00450.91

Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, cyp2d7-2d6 hybrid gene) (list separately in addition to code for primary procedure)

00450.91

Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (list separately in addition to code for primary procedure)

00450.91

Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5' gene duplication/multiplication) (list separately in addition to code for primary procedure)

00450.91

Cyp2d6 (cytochrome p450, family 2, subfamily d, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3' gene duplication/ multiplication) (list separately in addition to code for primary procedure)

00043.43

Immunoglobulin paraprotein (m-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype

03520.00

Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein m130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy

00246.92

Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service

00167.35

Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations

00720.00

Red blood cell antigen typing, dna, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens

00200.00

Infectious disease (bacterial and fungal), organism identification, blood culture, using rrna fish, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (mic)-based antimicrobial susceptibility

03159.42

Cardiology (heart transplant), mrna gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score

03159.42

Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection

00760.00

Oncology (melanoma), gene expression profiling by rtqpcr, prame and linc00518, superficial collection using adhesive patch(es)

01950.00

Oncology (cutaneous melanoma), mrna gene expression profiling by rt-pcr of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (ffpe) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)

02488.00

Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy

00062.14

Prescription drug monitoring, evaluation of 65 common drugs by lc-ms/ms, urine, each drug reported detected or not detected

07582.20

Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis

00771.98

Eosinophilic esophagitis, 2 protein biomarkers (eotaxin-3 [ccl26 {c-c motif chemokine ligand 26}] and major basic protein [prg2 {proteoglycan 2, pro eosinophil major basic protein}], enzyme-linked immunosorbent assays (elisa), specimen obtained by esophageal string test device, algorithm reported as probability of active or inactive eosinophilic esophagitis

00035.09

Human papillomavirus (hpv), high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), male urine

01743.95

Hereditary colon cancer disorders (eg, lynch syndrome, pten hamartoma syndrome, cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a combination of ngs, sanger, mlpa, and array cgh, with mmrna analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], epcam and grem1 [deletion/duplication only])

01303.95

Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of ngs, sanger, mlpa, and array cgh, with mmrna analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication])

01743.95

Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of ngs, sanger, mlpa, and array cgh, with mmrna analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], epcam [deletion/duplication only])

00950.00

Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (eclia) of tumor necrosis factor receptor 1a, receptor superfamily 2 (tnfr1, tnfr2), and kidney injury molecule-1 (kim-1) combined with longitudinal clinical data, including apol1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (rkfd)

00874.49

Gastric emptying, serial collection of 7 timed breath specimens, non-radioisotope carbon-13 (13c) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of 13co2 excretion

00016.00

Clostridium difficile toxin(s) antigen detection by immunoassay technique, stool, qualitative, multiple-step method

04950.00

Gastroenterology (barrett's esophagus), whole slide-digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, amacr, p53, cd68, cox-2, cd45ro, hif1a, her-2, k20) and morphology, formalin-fixed paraffinembedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer

00142.63

Infectious disease (aspergillus species), real-time pcr for detection of dna from 4 species (a. fumigatus, a. terreus, a. niger, and a. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species

00027.11

Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected

00682.29

Oncology (colon cancer), targeted kras (codons 12, 13, and 61) and nras (codons 12, 13, and 61) gene analysis utilizing formalin-fixed paraffin-embedded tissue

00356.13

Infectious agent detection and identification, targeted sequence analysis (16s and 18s rrna genes) with drugresistance gene

00760.00

Oncology (prostate), measurement of pca3 and tmprss2-erg in urine and psa in serum following prostatic massage, by rna amplification and fluorescencebased detection, algorithm reported as risk score

01938.01

Gastroenterology (barrett's esophagus), vim and ccna1 methylation analysis, esophageal cells, algorithm reported as likelihood for barrett's esophagus

00275.35

Respiratory infectious agent detection by nucleic acid (dna and rna), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for rna targets, each analyte reported as detected or not detected

00246.92

Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with lc-ms/ms, oral fluid, algorithm results reported as a patientcompliance measurement with risk of drug to drug interactions for prescribed medications

00840.65

Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3hydroxypropyl mercapturic acid (3-hpma), quinolinic acid, kynurenic acid), lcms/ms, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain

02753.25

Transplantation medicine, quantification of donor-derived cell-free dna using whole genome next-generation sequencing, plasma, reported as percentage of donorderived cell-free dna in the total cell-free dna

00083.76

Cardiology, ceramides by liquid chromatography-tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events

02510.21

Oncology (b-cell lymphoma classification), mrna, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal b-cell lymphoma (pmbcl) and diffuse large b-cell lymphoma (dlbcl) with cell of origin subtyping in the latter

00509.20

Sickle cell disease, microfluidic flow adhesion (vcam-1), whole blood

00526.23

Sickle cell disease, microfluidic flow adhesion (p-selectin), whole blood

00357.63

Mechanical fragility, rbc, shear stress and spectral analysis profiling

01303.95

Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis and deletion/duplication analysis panel (atm, brca1, brca2, cdh1, chek2, palb2, pten, and tp53)